Skip to content Skip to footer
Subscribe Now
Viewpoints_Garret Hampton
VIEWPOINTS
Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC
Shots:Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2  activating mutations for treatment with ENHERTUGarret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographiesThe interview highlights how Thermo Fisher is working to develop accessible CDx solutions…
October 25, 20220Comments
Viewpoints_Josh Rubel
VIEWPOINTS
Josh Rubel, CCO at MDClone, Shares Insights on the Partnership with MCI Onehealth to Accelerate Research through Global Clinical Intelligence Offering
Shots:Josh spoke about the collaboration with MCI Onehealth. The collaboration will provide access to high-value data insights as a service for an array of research, clinical, and data science needsJosh also talked about MDClone’s ADAMS platform which has a unique ability to convert datasets and cohorts of interest into synthetic files that are…
October 19, 20220Comments
Disease of the Month: Cerebral Palsy
INSIGHTS+
Disease of the Month: Cerebral Palsy
INTRODUCTIONCerebral Palsy is a group of neurological disorders which affect motor and developmental skills. It causes disability in muscle tone, movement, balance, and posture. It is the most common motor disability in childhood with an estimated prevalence ranging from 1-4 per 1,000 live births. The incidence of CP is more in preterm or low…
October 18, 20220Comments
Viewpoints_Jonathan Wall
VIEWPOINTS
Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis
Shots:Jonathan spoke about the data presented by Attralus at the XVIII International Symposium on Amyloidosis (ISA) as both oral and poster presentationsJonathan also talked about its lead candidate, AT-01. He discussed the study design of the P-I/II clinical trial evaluating AT-01The interview highlights Attralus vision to develop innovative medicines to improve the…
October 17, 20220Comments